Loading...
•
Mar 31, 2020
Arcus Biosciences Q1 2020 Earnings Report
Arcus Biosciences reported financial results for Q1 2020 and provided corporate updates.
Key Takeaways
Arcus Biosciences reported a net loss of $27.8 million for the first quarter ended March 31, 2020. Collaboration and license revenue was $1.8 million. Research and development expenses were $23.1 million, and general and administrative expenses were $7.0 million. Cash, cash equivalents and investments in marketable securities were $157.9 million as of March 31, 2020.
Received FDA clearance for ARC-6, a prostate cancer platform trial.
Completed enrollment of the first two cohorts in the dose-escalation portion of ARC-8, a trial evaluating AB680 in combination with zimberelimab and gemcitabine/nab-paclitaxel in patients with pancreatic cancer.
Initiation of enrollment in ARC-6, a Phase 1b/2 platform trial expanding our strategy in prostate cancer, evaluating various combinations of AB928, AB680 and zimberelimab, alone or in combination, with standard of care therapies for the treatment of mCRPC in the first half of 2020
Preliminary data from Phase 1b expansion trials investigating combinations with AB928 in multiple tumor types and settings, expected starting in mid-2020
Revenue by Segment
Forward Guidance
Arcus Biosciences continues to actively monitor the COVID-19 pandemic and its effects on its clinical trial operations, research and development programs, key vendors and employees. While the company does not anticipate any modifications to the timelines, this will depend on future developments which are currently unknown.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...